CD8A and neoplasm: Subsequent studies of EVs secreted from melanoma and prostate cancer cells revealed that they express programmed death-ligand 1 (PD-L1) on their surface, which suppresses the function of CD8+ T cells and facilitates tumor growth (90–93).